News | March 03, 2024
Briefs: SMS Pharmaceuticals and Vimta Labs
EDQM conducts GMP inspection of SMS Pharmaceuticals’ API facility
EDQM conducts GMP inspection of SMS Pharmaceuticals’ API facility
The agreement licenses the company to launch in the United States, in February 2025, once approved by the U.S. FDA
Highlighting fully integrated organization, robust portfolio, and strategic priorities to drive long-term sustainable growth
_in_Mizushima,_Japan_256_384.jpg)
Contributing to lower risk of potentially carcinogenic nitrosamine impurities in pharmaceuticals
_Rupak_Singla_256_384.jpg)
Experts discussed the latest innovations, challenges, & collaborative solutions in the fight against TB at NHWIC-2024 held at AIIMS, Delhi
Orchid is the first company from India, ever to have invented a product which has received a New Drug Approval (NDA) from USFDA
We are achieving the target of developed India by making our young children healthy today
VELSIPITY is the first and only oral advanced ulcerative colitis therapy approved for use in patients 16 years of age or older in the EU
The acquisition of Aiolos includes AIO-001, a potentially best-in-class, long-acting antithymic stromal lymphopoietin (TSLP) monoclonal antibody
The new tests can support clinical decision making when prescribing direct oral anticoagulants for stroke prevention
Subscribe To Our Newsletter & Stay Updated
